Rabbit Polyclonal P2Y14 antibody. Suitable for WB and reacts with Human samples. Cited in 3 publications. Immunogen corresponding to Synthetic Peptide within Human P2RY14.
View Alternative Names
GPR105, KIAA0001, P2RY14, P2Y purinoceptor 14, P2Y14, G-protein coupled receptor 105, UDP-glucose receptor
- WB
Unknown
Western blot - Anti-P2Y14 antibody (AB136264)
All lanes:
Western blot - Anti-P2Y14 antibody (ab136264) at 1/500 dilution
All lanes:
K562 cell lysate at 30 µg
Predicted band size: 39 kDa
false
- WB
CiteAb
Western blot - Anti-P2Y14 antibody (AB136264)
P2Y14 western blot using anti-P2Y14 antibody ab136264. Publication image and figure legend from Ma, J., Wei, K., et al., 2020, Nat Commun, PubMed 32286295.
ab136264 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab136264 please see the product overview.
UDPG regulates inflammatory macrophages via P2Y14 receptor.a–cPgm1, Ugp2 or Gys1 siRNA transfected BMDMs were stimulated with IFN-γ/LPS for 24 h, Nos2, Tnf, Il6 and Il1b expression was determined by real-time PCR. dGys1, Pgm1 or Ugp2 siRNA transfected BMDMs were stimulated with IFN-γ/LPS for 24 h, UDPG in supernatants was determined by ELISA. e IFN-γ/LPS-stimulated BMDMs were treated with UDPG (0, 100 or 200 μM) for 24 or 36 h, Nos2, Tnf, Il6, and Il1b expression was determined by real-time PCR (left), iNOS, TNF and IL-6 expression was determined by western blot (middle) and ELISA (right). f, gUgp2 or G6pdx siRNA transfected BMDMs were stimulated with IFN-γ/LPS ± UDPG (200 μM) for 24 or 36 h, Nos2, Tnf, Il6, and Il1b expression was determined by real-time PCR (left), iNOS, TNF and IL-6 expression was determined by western blot (middle) and ELISA (right). hPygl or G6pdx siRNA transfected BMDMs were stimulated with IFN-γ/LPS for 24 h, UDPG in supernatants was determined by ELISA. i BMDMs were pretransfected with siRNA (Pygl or G6pdx) for 24 h prior to stimulation with IFN-γ/LPS for 6 h and switched to 13C-glucose for 6 h, lysed cells were analyzed by LC-MS/MS to determine m + 6-labeled UDPG. j, k P2Y14 receptor expression in untreated, IFN-γ/LPS- or IL-4-treated BMDMs was determined by real-time PCR (j) and western blot (k). l, m IFN-γ/LPS-stimulated BMDMs were treated with UDPG (0, 100 or 200 μM) for 24 or 36 h, P2Y14 expression was determined by real-time PCR (l) and western blot (m). n–pP2ry14 siRNA transfected BMDMs were stimulated with or without IFN-γ/LPS for 24 or 36 h, Nos2, Tnf, Il6, and Il1b expression was determined by real-time PCR (n), iNOS, TNF, and IL-6 expression was determined by western blot (o) and ELISA (p). Unless otherwise specified, n = 3 biologically independent experiments were performed. Data are presented as mean ± SEM. P values were calculated using one-way ANOVA. **p < 0.01, ****p < 0.0001.
false
Reactivity data
Properties and storage information
Form
Purification technique
Purification notes
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
P2Y14 receptor participates in immune responses by modulating the function of various leukocytes. It does not exist as part of large multimeric complexes but interacts with the cellular machinery to influence the behavior of the immune system. Through its interaction with extracellular nucleotides and sugars P2Y14 impacts immune cell chemotaxis and cytokine release which are critical for immune regulation.
Pathways
P2Y14 receptor plays a significant role in inflammatory signaling pathways and chemotaxis. It interacts with other proteins such as P2Y12 to modulate the activation and recruitment of immune cells. P2Y14 links to key pathways such as those involving GPCR signaling impacting immune cell movement and inflammation processes.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (3)
Recent publications for all applications. Explore the full list and refine your search
Journal of Cancer 15:632-644 PubMed38213736
2024
Applications
Unspecified application
Species
Unspecified reactive species
Nature communications 11:1769 PubMed32286295
2020
Applications
Unspecified application
Species
Unspecified reactive species
FEBS letters 588:2936-43 PubMed24911208
2014
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com